David J Taber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1088013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management. Pharmacotherapy, 2021, 41, 119-131.	2.6	62
2	Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation, 2017, 101, 2931-2938.	1.0	57
3	Early Aspirin Therapy May Reduce Hepatic Artery Thrombosis in Liver Transplantation. Transplantation Proceedings, 2013, 45, 330-334.	0.6	56
4	Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With LeftÂVentricular Assist Devices. Journal of the American College of Cardiology, 2019, 73, 1769-1778.	2.8	55
5	Sustainability of Improvements in Medication Adherence through a Mobile Health Intervention. Progress in Transplantation, 2015, 25, 217-223.	0.7	53
6	Hydroxyethyl Starch and Acute Kidney Injury in Orthotopic Liver Transplantation. Anesthesia and Analgesia, 2015, 120, 619-626.	2.2	51
7	A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. American Journal of Transplantation, 2020, 20, 1969-1983.	4.7	51
8	Does Bioequivalence Between Modified Cyclosporine Formulations Translate into Equal Outcomes?. Transplantation, 2005, 80, 1633-1635.	1.0	49
9	Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm. Clinical Transplantation, 2013, 27, 732-741.	1.6	47
10	The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation. American Journal of Nephrology, 2017, 45, 91-98.	3.1	47
11	Africanâ€American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients. Pharmacotherapy, 2015, 35, 569-577.	2.6	46
12	Improved Patient Safety and Outcomes With a Comprehensive Interdisciplinary Improvement Initiative in Kidney Transplant Recipients. American Journal of Medical Quality, 2013, 28, 103-112.	0.5	45
13	Prospective Randomized Controlled Trial of Rabbit Antithymocyte Globulin Compared With IL-2 Receptor Antagonist Induction Therapy in Kidney Transplantation. Annals of Surgery, 2014, 259, 888-893.	4.2	43
14	Leflunomide Efficacy and Pharmacodynamics for the Treatment of BK Viral Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1003-1009.	4.5	42
15	Preâ€existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clinical Transplantation, 2013, 27, 274-282.	1.6	41
16	Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. American Journal of Surgery, 2017, 213, 666-672.	1.8	38
17	Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1539-1551.	4.5	37
18	Belatacept in Solid Organ Transplant. Transplantation, 2018, 102, 1440-1452.	1.0	36

#	Article	IF	CITATIONS
19	Inclusion of Dynamic Clinical Data Improves the Predictive Performance of a 30-Day Readmission Risk Model in Kidney Transplantation. Transplantation, 2015, 99, 324-330.	1.0	34
20	Twenty years of evolving trends in racial disparities for adult kidney transplant recipients. Kidney International, 2016, 90, 878-887.	5.2	34
21	Impact of the New Kidney Allocation System on Perioperative Outcomes and Costs in Kidney Transplantation. Journal of the American College of Surgeons, 2017, 224, 585-592.	0.5	34
22	Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Annals of Pharmacotherapy, 2020, 54, 1185-1193.	1.9	32
23	Medication Errors and Adverse Drug Events in Kidney Transplant Recipients: Incidence, Risk Factors, and Clinical Outcomes. Pharmacotherapy, 2012, 32, 1053-1060.	2.6	30
24	Clinical and Economic Outcomes Associated with Medication Errors in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 960-966.	4.5	30
25	Effect of frailty on resource use and cost for Medicare patients. Journal of Comparative Effectiveness Research, 2018, 7, 817-825.	1.4	30
26	Clinical Outcomes Associated With the Early Postoperative Use of Heparin in Pancreas Transplantation. Transplantation, 2014, 97, 681-685.	1.0	27
27	Predicting and preventing readmissions in kidney transplant recipients. Clinical Transplantation, 2016, 30, 779-786.	1.6	26
28	Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. American Journal of Health-System Pharmacy, 2019, 76, 1143-1149.	1.0	25
29	Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. World Journal of Transplantation, 2016, 6, 697.	1.6	25
30	A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 131-139.	4.5	24
31	Use of Renin—Angiotensin—Aldosterone System Inhibitors Within the First Eight to Twelve Weeks After Renal Transplantation. Annals of Pharmacotherapy, 2008, 42, 116-120.	1.9	23
32	Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients. Transplantation, 2016, 100, 1550-1557.	1.0	23
33	Overall Graft Loss Versus Death-Censored Graft Loss. Transplantation, 2017, 101, 402-410.	1.0	23
34	Hypertension after Kidney Transplantation: A Pathophysiologic Approach. Current Hypertension Reports, 2013, 15, 458-469.	3.5	22
35	Are Thiazide Diuretics Safe and Effective Antihypertensive Therapy in Kidney Transplant Recipients. American Journal of Nephrology, 2013, 38, 285-291.	3.1	22
36	The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clinical Transplantation, 2014, 28, 862-868.	1.6	22

#	Article	IF	CITATIONS
37	Significant Racial Differences in the Key Factors Associated with Early Graft Loss in Kidney Transplant Recipients. American Journal of Nephrology, 2014, 40, 19-28.	3.1	22
38	Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 776-784.	4.5	22
39	Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatric Transplantation, 2016, 20, 44-48.	1.0	21
40	A National Survey Assessing the Current Workforce of Transplant Pharmacists Across Accredited U.S. Solid Organ Transplant Programs. American Journal of Transplantation, 2015, 15, 2683-2690.	4.7	19
41	Influence of mild obesity on outcome of simultaneous pancreas and kidney transplantation. Journal of Gastrointestinal Surgery, 2003, 7, 1096-1101.	1.7	18
42	Generic Immunosuppression: Deciphering the Message Our Patients are Receiving. Annals of Pharmacotherapy, 2012, 46, 671-677.	1.9	18
43	Can Preemptive Cytomegalovirus Monitoring Be As Effective As Universal Prophylaxis When Implemented As the Standard of Care in Patients at Moderate Risk?. Transplantation, 2010, 89, 1218-1223.	1.0	17
44	Improving the Perioperative Value of Care for Vulnerable Kidney Transplant Recipients. Journal of the American College of Surgeons, 2013, 216, 668-676.	0.5	17
45	Concern for Lost Income Following Donation Deters Some Patients From Talking to Potential Living Donors. Progress in Transplantation, 2016, 26, 292-298.	0.7	17
46	Impact of Cardiovascular Risk Factors on Graft Outcome Disparities in Black Kidney Transplant Recipients. Hypertension, 2016, 68, 715-725.	2.7	17
47	Long-term Assessment of NSAID Prescriptions and Potential Nephrotoxicity Risk in Adult Kidney Transplant Recipients. Transplantation, 2019, 103, 2675-2681.	1.0	17
48	Virtual Crossmatching in Kidney Transplantation: The Wait Is Over. Journal of the American College of Surgeons, 2020, 230, 373-379.	0.5	16
49	Long-Term Efficacy of Induction Therapy With Anti–Interleukin-2 Receptor Antibodies or Thymoglobulin Compared With No Induction Therapy in Renal Transplantation. Transplantation Proceedings, 2008, 40, 3401-3407.	0.6	15
50	Ethnic and geographic variations in multimorbidty: Evidence from three large cohorts. Social Science and Medicine, 2018, 211, 198-206.	3.8	15
51	Assessment of magnetic resonance imaging derived fat fraction as a sensitive and reliable predictor of myosteatosis in liver transplant recipients. Hpb, 2020, 22, 102-108.	0.3	15
52	Impact of a multidisciplinary multimodal opioid minimization initiative in kidney transplant recipients. Clinical Transplantation, 2020, 34, e14006.	1.6	15
53	Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol. JMIR Research Protocols, 2018, 7, e59.	1.0	15
54	Utility of the Surgical Apgar Score in Kidney Transplantation. Progress in Transplantation, 2016, 26, 122-128.	0.7	14

#	Article	IF	CITATIONS
55	Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSAFE Rx randomized controlled trial. American Journal of Health-System Pharmacy, 2021, 78, 1287-1293.	1.0	14
56	Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 3428-3435.	4.7	14
57	Association Between Patient Satisfaction and Outcomes in Kidney Transplant. American Journal of Medical Quality, 2015, 30, 180-185.	0.5	13
58	Morbid obesity and functional status as predictors of surgical complication after renal transplantation. American Journal of Surgery, 2018, 215, 663-668.	1.8	13
59	Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clinical Transplantation, 2010, 24, 40-47.	1.6	12
60	Ambulatory Care Coordination Issues With Dual Use Veteran Organ Transplant Recipients. Progress in Transplantation, 2017, 27, 187-191.	0.7	12
61	Pharmacistâ€led, technologyâ€assisted study to improve medication safety, cardiovascular risk factor control, and racial disparities in kidney transplant recipients. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 81-88.	1.0	12
62	Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility. Mental Health Clinician, 2019, 9, 1-5.	1.0	12
63	No Difference Between Smokers, Former Smokers, or Nonsmokers in the Operative Outcomes of Laparoscopic Donor Nephrectomies. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2009, 19, 153-156.	0.8	11
64	The Impact of Cardiovascular Disease and Risk Factor Treatment on Ethnic Disparities in Kidney Transplant. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 243-250.	2.0	11
65	Randomized controlled trial assessing the impact of everolimus and lowâ€exposure tacrolimus on graft outcomes in kidney transplant recipients. Clinical Transplantation, 2019, 33, e13679.	1.6	11
66	Evaluation of Estimated and Measured Creatinine Clearances for Predicting the Pharmacokinetics of Vancomycin in Adult Liver Transplant Recipients. Therapeutic Drug Monitoring, 2003, 25, 67-72.	2.0	10
67	Inflammatory Biomarkers, Clycemic Variability, Hypoglycemia, and Renal Transplant Outcomes. Transplantation, 2014, 98, 632-639.	1.0	10
68	Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: A retrospective analysis. Blood Pressure, 2015, 24, 14-22.	1.5	10
69	Hospital admissions and emergency department visits among kidney transplant recipients. Clinical Transplantation, 2019, 33, e13522.	1.6	10
70	Association of High Burden of End-stage Kidney Disease With Decreased Kidney Transplant Rates With the Updated US Kidney Allocation Policy. JAMA Surgery, 2021, 156, 639.	4.3	10
71	Management of Hypertension in Renal Transplant Patients: A Comprehensive Review of Nonpharmacologic and Pharmacologic Treatment Strategies. Annals of Pharmacotherapy, 2010, 44, 1259-1270.	1.9	9
72	Cardiovascular Drug Shortages. Annals of Pharmacotherapy, 2014, 48, 1177-1186.	1.9	9

#	Article	IF	CITATIONS
73	Development of a Predictive Model for Drugâ€Related Problems in Kidney Transplant Recipients. Pharmacotherapy, 2017, 37, 159-169.	2.6	9
74	Development and future deployment of a 5 years allograft survival model for kidney transplantation. Nephrology, 2019, 24, 855-862.	1.6	9
75	Early Assessment of National Kidney Allocation Policy Change. Journal of the American College of Surgeons, 2022, 234, 565-570.	0.5	9
76	Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transplant International, 2010, 23, 500-505.	1.6	8
77	Depression, Resource Utilization, and Outcomes Following Liver Transplant. Progress in Transplantation, 2016, 26, 270-276.	0.7	8
78	A randomized, prospective comparison of transition to sirolimusâ€based <scp>CNI</scp> â€minimization or withdrawal in African American kidney transplant recipients. Clinical Transplantation, 2016, 30, 528-533.	1.6	8
79	Association of Pretransplantion Opioid Use with Graft Loss or Death in Liver Transplantation Patients with Model of End-Stage Liver Disease Exceptions. Journal of the American College of Surgeons, 2018, 226, 651-659.	0.5	8
80	Patterns of dispensed opioids after tonsillectomy in children and adolescents in South Carolina, United States, 2010–2017. International Journal of Pediatric Otorhinolaryngology, 2021, 143, 110636.	1.0	8
81	Non-Adherence to Appointments is a Strong Predictor of Medication Non-Adherence and Outcomes in Kidney Transplant Recipients. American Journal of the Medical Sciences, 2021, 362, 381-386.	1.1	8
82	The impact of diabetes on ethnic disparities seen in kidney transplantation. Ethnicity and Disease, 2013, 23, 238-44.	2.3	8
83	Implementation of a collaborative drug therapy management service for inpatients receiving direct thrombin inhibitors. American Journal of Health-System Pharmacy, 2009, 66, 1297-1303.	1.0	7
84	Clinical and Economic Analysis of Delayed Administration of Antithymocyte Globulin for Induction Therapy in Kidney Transplantation. Progress in Transplantation, 2013, 23, 33-38.	0.7	7
85	Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation. Journal of Pharmacy Practice, 2016, 29, 97-102.	1.0	7
86	Improvement in immunosuppression therapy monitoring in organ transplant recipients. American Journal of Health-System Pharmacy, 2017, 74, S67-S74.	1.0	7
87	Evolving Trends in Racial Disparities for Peri-Operative Outcomes with the New Kidney Allocation System (KAS) Implementation. Journal of Racial and Ethnic Health Disparities, 2018, 5, 1171-1179.	3.2	7
88	Renal Function Variability: An Independent Risk Factor for Graft Loss and Death following Kidney Transplantation. American Journal of Nephrology, 2018, 47, 191-199.	3.1	7
89	Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients. Surgery, 2018, 163, 430-435.	1.9	7
90	The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes. Annals of Pharmacotherapy, 2019, 53, 675-682.	1.9	7

#	Article	IF	CITATIONS
91	Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients. Annals of Transplantation, 2018, 23, 119-128.	0.9	7
92	Review and Evaluation of mHealth Apps in Solid Organ Transplantation: Past, Present, and Future. Transplantation Direct, 2022, 8, e1298.	1.6	7
93	Racial Comparisons of Everolimus Pharmacokinetics and Pharmacodynamics in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 753-759.	2.0	6
94	Timing of Factor VIIa in Liver Transplantation Impacts Cost and Clinical Outcomes. Pharmacotherapy, 2013, 33, 483-488.	2.6	6
95	Lithium Dosing Equations. Annals of Pharmacotherapy, 2014, 48, 596-600.	1.9	6
96	The Concept of a Composite Perioperative Quality Index in Kidney Transplantation. Journal of the American College of Surgeons, 2014, 218, 588-597.	0.5	6
97	Optimizing finite resources: Pharmacist chart reviews in an outpatient kidney transplant clinic. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 613-620.	1.5	6
98	Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clinical Transplantation, 2015, 29, 222-226.	1.6	6
99	Value of Solid Organ Transplant-Trained Pharmacists in Transplant Infectious Diseases. Current Infectious Disease Reports, 2015, 17, 475.	3.0	6
100	Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Annals of Surgery, 2017, 266, 450-456.	4.2	6
101	Improving medication safety and cardiovascular risk factor control to mitigate disparities in African-American kidney transplant recipients: Design and methods. Contemporary Clinical Trials Communications, 2018, 9, 1-6.	1.1	6
102	Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2021, 43, 401-407.	2.0	6
103	Graft outcomes in pediatric kidney transplantation: Focus on the role of race. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2012, 23, 684.	0.3	6
104	Building a business plan to support a transplantation pharmacy practice model. American Journal of Health-System Pharmacy, 2014, 71, 751-757.	1.0	5
105	Valganciclovir (<scp>VGCV</scp>) followed by cytomegalovirus (<scp>CMV</scp>) hyperimmune globulin compared to <scp>VGCV</scp> for 200Adays in abdominal organ transplant recipients at high risk for <scp>CMV</scp> infection: A prospective, randomized pilot study. Transplant Infectious Disease. 2017. 19. e12779.	1.7	5
106	Racial–Geographic Disparity in Lipid Management in Veterans with Type 2 Diabetes: A 10-Year Retrospective Cohort Study. Health Equity, 2019, 3, 472-479.	1.9	5
107	The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transplant International, 2019, 32, 84-94.	1.6	5
108	Impact of Race and Location of Residence on Statin Treatment Among Veterans With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2020, 125, 1492-1499.	1.6	5

#	Article	IF	CITATIONS
109	Preliminary assessment of safety and adherence to a onceâ€daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. Clinical Transplantation, 2020, 34, e13844.	1.6	5
110	Maintaining Equity and Access: Successful Implementation of a Virtual Kidney Transplantation Evaluation. Journal of the American College of Surgeons, 2021, 232, 444-449.	0.5	5
111	Is cirrhosis a contraindication to laparoscopic cholecystectomy?. American Surgeon, 2015, 81, 52-5.	0.8	5
112	Risk factors and trajectories of opioid use following total knee replacement. Knee Surgery and Related Research, 2022, 34, 18.	4.2	5
113	Potential Differences in Kidney Allograft Outcomes Between Ethnicities When Converting to Sirolimus Base Immunosuppression. Transplantation Proceedings, 2009, 41, 4131-4137.	0.6	4
114	Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors. American Journal of Health-System Pharmacy, 2012, 69, 1993-1998.	1.0	4
115	Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes?. Medicine (United) Tj ETQq1	1 0.78431 1.0	4 rgBT /Over
116	Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation. Surgery, 2017, 161, 830-836.	1.9	4
117	Assessment of risk factors for increased resource utilization in kidney transplantation. Journal of Surgical Research, 2018, 222, 195-202.e2.	1.6	4
118	It is time for board certification in transplant pharmacotherapy. American Journal of Transplantation, 2018, 18, 2370-2371.	4.7	4
119	The impact of pretransplant opioid exposure on healthcare utilization and costs in kidney transplant. Pharmacotherapy, 2021, 41, 6-13.	2.6	4
120	Facilitated Regional Collaboration and In-Hospital Surgical Complication. Journal of the American College of Surgeons, 2021, 232, 536-543.	0.5	4
121	Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e13821.	1.0	4
122	Incidence and patterns of persistent opioid use in children following appendectomy. Journal of Pediatric Surgery, 2022, 57, 912-919.	1.6	4
123	Use of Bone Health Protocol to Identify and Prevent Bone Disease in Kidney and Pancreas Transplant Recipients. Annals of Pharmacotherapy, 2007, 41, 944-950.	1.9	3
124	Feasibility and Functional Testing for Frailty in Chronic Kidney Disease. Progress in Transplantation, 2018, 28, 299-300.	0.7	3
125	Longâ€standing diabetes mellitus and pancreas transplantation: An avenue to increase utilization of an ideal treatment modality. Clinical Transplantation, 2019, 33, e13695.	1.6	3
126	The impact of race on metabolic, graft, and patient outcomes after pancreas transplantation. American Journal of Surgery, 2022, 223, 812-816.	1.8	3

#	Article	IF	CITATIONS
127	The Magnitude and Potential Causes of Sex Disparities in Statin Therapy in Veterans with Type 2 Diabetes: A 10-year Nationwide Longitudinal Cohort Study. Women's Health Issues, 2022, 32, 274-283.	2.0	3
128	New chronic opioid use in Medicaid patients following cholecystectomy. Surgery Open Science, 2022, 9, 101-108.	1.2	3
129	Phenotype of immunosuppression reduction after kidney transplantation. Clinical Transplantation, 2020, 34, e14047.	1.6	2
130	Medication nonadherence monitoring and management in adult kidney transplantation: A survey of practices and perceptions at <scp>USâ€based</scp> transplant programs. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1100-1108.	1.0	2
131	A Critical Analysis of the Specific Pharmacist Interventions and Risk Assessments During the 12-Month TRANSAFE Rx Randomized Controlled Trial. Annals of Pharmacotherapy, 2022, 56, 685-690.	1.9	2
132	Surgical Outcomes Improvement and Health Inequity in a Regional Quality Collaborative. Journal of the American College of Surgeons, 2022, 234, 607-614.	0.5	2
133	A Dialysis Center Educational Video Intervention Increases Patient Self-Efficacy and Kidney Transplant Evaluations. Progress in Transplantation, 2022, 32, 27-34.	0.7	2
134	Medical Management Considerations for Patients With Lung Transplantation. Journal of Pharmacy Practice, 2001, 14, 258-276.	1.0	1
135	Racial Disparity Outcomes in Patients Undergoing Hepatectomy: Is Baseline Kidney Function a Potential Explanation?. Progress in Transplantation, 2015, 25, 257-262.	0.7	1
136	Protocolâ€based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients—A singleâ€center experience with a large African American population. Clinical Transplantation, 2019, 33, e13701.	1.6	1
137	An Evaluation of Statin Use Among Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Across Multiple Health Care Systems. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1090-1098.	0.9	1
138	Patterns of emergency department utilization between transplant and nonâ€transplant centers and impact on clinical outcomes in kidney recipients. Clinical Transplantation, 2020, 34, e13983.	1.6	1
139	Costs and factors associated with heart failure following kidney transplantation – a singleâ€center retrospective cohort study. Transplant International, 2020, 33, 414-422.	1.6	1
140	Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. ASAIO Journal, 2021, 67, 1277-1283.	1.6	1
141	Patientâ€reported medication adherence and tolerability: Results of a prospective observational study. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 271-279.	1.0	1
142	Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race. Experimental and Clinical Transplantation, 2019, 17, 707-713.	0.5	1
143	Transplant clinical pharmacy services improve cardiovascular risk factor management and control in Veteran organ transplant recipients. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 280-287.	1.0	1
144	COMPARISON OF CMV PROPHYLAXIS AND PREEMPTIVE THERAPY IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS Transplantation, 2000, 69, S181.	1.0	0

#	Article	IF	CITATIONS
145	LONG-TERM PANCREAS GRAFT SURVIVAL EXCEEDS LONG-TERM KIDNEY GRAFT SURVIVAL IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION: DIFFERENTIAL EFFECT OF CHRONIC CALCINEURIN INHIBITOR THERAPY?. Transplantation, 2003, 76, S62.	1.0	Ο
146	The clinical and economic impact of biliary complications following liver transplantation. Journal of the American College of Surgeons, 2014, 219, e184.	0.5	0
147	Characterization of Potentially Unsafe Ambulatory Antibiotic Use and Associated Outcomes in an Adult Kidney Transplant Population. Annals of Pharmacotherapy, 2018, 52, 974-982.	1.9	Ο
148	Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Therapeutic Drug Monitoring, 2020, 42, 415-420.	2.0	0
149	Impact of Anesthesiologist Experience on Early Outcomes in Adult Orthotopic Liver Transplantation. Transplantation Proceedings, 2021, 53, 1665-1669.	0.6	Ο
150	Clinical Outcomes of Older Kidney Transplant Recipients. American Journal of the Medical Sciences, 2021, 362, 130-134.	1.1	0
151	Challenges for expansion of thoracic transplant clinical pharmacy in a developing country: comparison with U.S. accredited centres and call for action. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	1.5	Ο